Valuation: BriaCell Therapeutics Corp.

Market Cap 3.28Cr 2.88Cr 2.66Cr 2.45Cr 4.64Cr 313.92Cr 4.73Cr 32Cr 12Cr 154.16Cr 12Cr 12Cr 532.39Cr P/E 2024
-2.56x
P/E 2025 -0.12x
Enterprise Value 1.49Cr 1.31Cr 1.21Cr 1.12Cr 2.11Cr 142.92Cr 2.15Cr 14Cr 5.67Cr 70Cr 5.61Cr 5.48Cr 242.38Cr EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
99.49%
Yield 2024 *
-
Yield 2025 -
1 day-4.48%
1 week+6.60%
Current month+14.87%
1 month+40.26%
3 months-12.48%
6 months-64.98%
Current year-45.61%
1 week 4.84
Extreme 4.84
5.64
1 month 3.81
Extreme 3.81
5.64
Current year 3.68
Extreme 3.68
16.5
1 year 3.68
Extreme 3.68
27.2
3 years 3.68
Extreme 3.68
1,543.5
5 years 3.68
Extreme 3.68
2,362.5
10 years 3.68
Extreme 3.68
11,250.11
Manager TitleAgeSince
Chief Executive Officer 70 01/11/2016
Director of Finance/CFO 54 01/02/2016
Chief Tech/Sci/R&D Officer 56 01/05/2021
Director TitleAgeSince
Director/Board Member 70 01/11/2016
Chairman 41 24/04/2019
Director/Board Member 74 07/03/2019
Date Insider Type Main position Quantity % Market Cap.
19/02Option

Chief Technology Officer

30,000 0.4830%
19/02Option

Chief Financial Officer

30,000 0.4830%
19/02Option

Chief Technology Officer

30,000 0.4830%
Change 5-day change 1-year change 3-year change Capi.($)
-4.48%+6.60%-80.90%-99.58% 3.28Cr
-2.48%-2.22%+55.85%+79.12% 5.35TCr
-0.55%-6.57%+58.09%+128.31% 5.42TCr
-5.60%-2.15%+11.16%+420.46% 2.37TCr
-1.55%-4.11%-20.21%-17.75% 2.28TCr
+1.07%+2.12%+40.41%-8.17% 1.95TCr
+1.87%+4.16%+38.13%-26.42% 1.78TCr
-2.72%-4.04%+187.08%+362.09% 1.6TCr
-1.79%-3.70%+44.40%+650.00% 1.54TCr
-0.81%+0.92%+24.92%+189.61% 1.41TCr
Average -1.75%-0.85%+35.89%+167.77% 2.37TCr
Weighted average by Cap. -1.55%-1.99%+48.25%+162.67%

Financials

2024 2025
Net sales - -
Net income -47.91L -42.03L -38.92L -35.81L -67.74L -46Cr -69.06L -4.64Cr -1.82Cr -23Cr -1.8Cr -1.76Cr -78Cr -2.63Cr -2.31Cr -2.14Cr -1.97Cr -3.72Cr -251.84Cr -3.79Cr -25Cr -9.99Cr -123.67Cr -9.88Cr -9.66Cr -427.1Cr
Net Debt -9L -8L -7L -6L -12.19L -8.25Cr -12.43L -83.47L -32.74L -4.05Cr -32.37L -31.66L -14Cr -1.79Cr -1.57Cr -1.45Cr -1.34Cr -2.53Cr -171Cr -2.58Cr -17Cr -6.78Cr -84Cr -6.71Cr -6.56Cr -290.01Cr
Logo BriaCell Therapeutics Corp.
BriaCell Therapeutics Corp. is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. Bria-IMT, its Phase 3 lead candidate, is a patented, off-the-shelf, cell-based, targeted immunotherapy that activates the patient’s immune system to specifically kill cancer cells without harming other cells. The Company is advancing its Bria-IMT targeted immunotherapy in combination with an immune check point inhibitor (Retifanlimab) in a pivotal Phase 3 study in metastatic breast cancer. It is also developing personalized off-the-shelf immunotherapies, Bria-OTS and Bria-OTS+, which provides a platform technology to develop personalized off-the-shelf immunotherapies for numerous types of cancer, and a soluble CD80 protein therapeutic which act both as a stimulator of the immune system, as well as an immune checkpoint inhibitor. Its pipeline also includes Bria-IMT + CPI, Bria-BRES/BRES+, Bria-PROS+, Bria-LUNG+ and Bria-MEL+.
Employees
16
Date Price Change Volume
13/26/13 CA$5.330 -4.48% 7,357
10/26/10 CA$5.580 +7.93% 14,492
09/26/09 CA$5.170 -1.90% 6,875
08/26/08 CA$5.270 +7.11% 22,074
07/26/07 CA$4.920 -1.60% 6,434

Quarterly revenue - Rate of surprise